325. Hereditary autoinflammatory syndrome Clinical trials / Disease details
Clinical trials : 5 / Drugs : 11 - (DrugBank : 6) / Drug target genes : 2 - Drug target pathways : 35
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05613868 (ClinicalTrials.gov) | March 2023 | 7/11/2022 | TPN-101 in Aicardi-Goutières Syndrome (AGS) | A Phase 2a Study of TPN-101 in Patients With Aicardi-Goutières Syndrome (AGS) | Aicardi-Goutières Syndrome (AGS) | Drug: TPN-101 | Transposon Therapeutics, Inc. | NULL | Not yet recruiting | 12 Months | N/A | All | 16 | Phase 2 | France;Italy;United Kingdom |